Please assess the completion status of the following clinical trial:

Trial Title: Resveratrol Trial for Relief of Pain in Pseudoachondroplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The diagnosis of pseudoachondroplasia is based on clinical assessment either in person or by photographic review by skeletal dysplasia specialist (JTH),~* Healthy beyond pseudoachondroplasia associated complications,~Exclusion Criteria:~* Current use of resveratrol~* Current use of blood thinners, lovastatin, ketoconazole, itraconazole, fexofenadine and triazolam.~* Other non-pseudoachondroplasia related health conditions, e.g. cancers.~* Pregnancy or breastfeeding. Women must use adequate contraception during the study.~* Participation in another clinical study and/or using investigational agents.~* Use of Non-steroid anti-inflammatory (NSAIDs) or aspirin.~* Current use of Alfentanil, Cyclosporine, Dihydroergotamine, Dofetilide, Ergotamine, Fentanyl, Flibanserin, Oxycodone, Pimavanserin, Pimozide, Quinidine, Saquinavir, Sirolimus, Tacrolimus, Temsirolimus, Theophylline, Tizanidine, Thioridazine, Fosphenytoin, Phenytoin or Warfarin.~* Baseline level of pain of 2 or higher on 10 point scale.~* Platelet count below 50,000 per ul on baseline complete blood count (CBC).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Resveratrol, Then Placebo (Type: EXPERIMENTAL): Participants first received Resveratrol 125 mg/day or 5 ml daily for 90 days. After a washout period of 30 days, they then received Placebo 5ml daily for 90 days.
- Placebo, Then Resveratrol (Type: PLACEBO_COMPARATOR): Participants first received Placebo 5ml daily for 90 days. After a washout period of 30 days, they then received Resveratrol 125 mg/day or 5 ml daily for 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).